ライフサイエンスコーパス: neutropenic

1 Most patients (90%) were not neutropenic.

2 Four patients were neutropenic.

3 tients developed evidence of infection while neutropenic.

4 transcriptional repressor protein GFI-1 are neutropenic.

5 repressor oncoprotein Gfi1 are unexpectedly neutropenic.

6 PM was diagnosed, all patients but one were neutropenic.

7 We find no role in virulence, however, among neutropenic and corticosteroid-suppressed mice with DC r

8 Efficacy is retained in neutropenic and corticosteroid-treated mice.

9 it(W/W-v) mice are MC-deficient, anemic, and neutropenic and have normal T cell compartments.

10 In both neutropenic and neutrophil-replete animals, the local re

11 terization revealed that these patients were neutropenic and NK cell deficient.

12 (DC) induced by intravenous infection among neutropenic and nonimmunosuppressed mice, as well as in

13 (levofloxacin) had 100% survivorship in both neutropenic and nonneutropenic groups.

14 There was no difference between the neutropenic and nonneutropenic patients in need of inten

15 e risk groups, the most vulnerable hosts are neutropenic and patients who are mechanically ventilated

16 t androgen receptor knockout (ARKO) mice are neutropenic and susceptible to acute bacterial infection

17 that gene-targeted Gfi-1-deficient mice are neutropenic and that Gfi-1 mutations cause human neutrop

18 dels were that the animals were not rendered neutropenic and they did not receive porcine mucin with

19 Median age was 59 years; 19% were neutropenic, and 22% were in an intensive care unit on t

20 Among these, 88% (22/25) were neutropenic, and 76% (19/25) had leukemia.

21 r syngeneic BMT, B6D2F(1) mice are no longer neutropenic, and by 3 wk, they demonstrate complete reco

22 d mice was decreased; however, mice were not neutropenic, and there was no difference in absolute blo

23 Neutropenic animals and liver macrophage (Kupffer cell)

24 Infection of neutropenic animals resulted in increased levels of viru

25 of lung dendritic cells was more immature in neutropenic animals than in nonneutropenic mice exposed

26 These findings coincided with the fact that neutropenic animals were more susceptible to A. hydrophi

27 mice with adhesion molecule deletions and in neutropenic animals.

28 he optimal exposures initially identified in neutropenic animals.

29 ork was undertaken in neutropenic versus non-neutropenic animals.

30 e to greatly elevated lung TNF expression in neutropenic as compared with nonneutropenic animals.

31 em cell transplantation and 640 (31.0%) were neutropenic at ICU admission.

32 seases, including infective endocarditis and neutropenic bacteremia.

33 inyl alcohol sponge wound model in mice made neutropenic by anti-Gr-1 Ab, as well as in cell culture.

34 Abdominal pain in neutropenic cancer patients presents a unique clinical c

35 This included 66,106 adult neutropenic cancer patients with 88,074 hospitalizations

36 Thromboembolism is frequent in hospitalized neutropenic cancer patients, including in perceived low-

37 Neutropenic colitis is characterized by right-sided colo

38 litaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related

39 he myeloid growth factors reduce the risk of neutropenic complications and may facilitate delivered d

40 myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity con

41 Neutropenic complications including febrile neutropenia

42 nd cost of these agents in the prevention of neutropenic complications including febrile neutropenia.

43 rade 3 to 4 toxicities were hematologic, few neutropenic complications resulted.

44 t variables that increase individual risk of neutropenic complications.

45 bacterial concentration is very high, under neutropenic conditions or when there is neutrophil dysfu

46 Thus, targeting IL-4 might be beneficial in neutropenic conditions with increased susceptibility to

47 In patients treated in a PE, a neutropenic diet did not prevent major infection or deat

48 A neutropenic diet is often used to prevent infection in p

49 ichia mikurensis" infection in a chronically neutropenic dog from Germany was confirmed by DNA sequen

50 Patients were neutropenic during a median of 14 days (9-22 d).

51 more age-dependent, associated with a modest neutropenic effect (9%, P = .012), demonstrated familial

52 t frequent causes of the abdominal pain were neutropenic enterocolitis (28%) and small bowel obstruct

53 Neutropenic enterocolitis (NEC) is a life-threatening di

54 to describe the population of patients with neutropenic enterocolitis admitted to an ICU and to inve

55 Data from critically ill patients with neutropenic enterocolitis are scarce.

56 s of this entity that can help differentiate neutropenic enterocolitis from other gastrointestinal co

57 Neutropenic enterocolitis is a serious, potentially leth

58 Neutropenic enterocolitis occurs in about 5.3% of patien

59 fungal disease reaches 20% in patients with neutropenic enterocolitis when enteritis is considered.

60 cally discussed in ICU patients admitted for neutropenic enterocolitis with radiologically assessed e

61 Neutropenic enterocolitis, also referred to as typhlitis

62 sis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transfussion-associated G

63 , diagnosis, and management of patients with neutropenic enterocolitis.

64 ient treatment is standard to manage febrile neutropenic episodes, although carefully selected patien

65 Acute toxicities during TPE included neutropenic fever (10%) and during XPE, grade 3 or 4 ora

66 de >/=3 adverse events were pneumonia (20%), neutropenic fever (11%), and diarrhea (6%).

67 related to neutropenia present at baseline: neutropenic fever (13 of 25 subjects) and septic death (

68 (3.3% v 0.0%; P =.004), hospitalizations for neutropenic fever (13.4% v 1.5%; P <.001), hospitalizati

69 ), thrombocytopenia (12%), anemia (12%), and neutropenic fever (2%).

70 rade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg.

71 common grade 3-4 adverse events overall were neutropenic fever (n=27) and pneumonia (n=18).

72 had serious adverse events, most frequently neutropenic fever (n=63, 38%), followed by pneumonia (n=

73 he most common grade 3-4 adverse events were neutropenic fever (seven patients [25%] in the 5-day gro

74 microg/kg did not reduce the probability of neutropenic fever after high-dose paclitaxel.

75 The incidence of neutropenic fever after the first cycle of paclitaxel 25

76 ohort, these infections were associated with neutropenic fever from an enteric source, and most isola

77 ogic or electrolyte abnormalities, including neutropenic fever in 18%.

78 ppression was the major adverse effect, with neutropenic fever in 28 (23%) of 124 courses of therapy.

79 Major infections or neutropenic fever occurred in 13% of patients.

80 There was no neutropenic fever or neutropenic sepsis.

81 All had neutropenic fever with symptoms of mucositis and/or ente

82 c: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocyto

83 well tolerated with anticipated cytopenias, neutropenic fever, and disease-related fever, diarrhea,

84 herapy was well tolerated, with transfusion, neutropenic fever, and infection remaining the most freq

85 ient (4%) died from sepsis in the context of neutropenic fever, infection, and haemorrhage in the 5-d

86 -associated thrombosis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transf

87 with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was observed in 9.3% of

88 e 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2.2 mg/kg dose; ther

89 tment breaks were mediport complications and neutropenic fever, which occurred mostly at that dose le

90 There was only 1 episode of neutropenic fever.

91 ncluded one grade 4 diarrhea and one grade 4 neutropenic fever.

92 nd 3% of patients receiving TAP experiencing neutropenic fever.

93 ms commonly used in the empiric treatment of neutropenic fever.

94 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.

95 adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events

96 Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.00

97 es were observed in 10% of patients, with no neutropenic fevers or treatment-related death.

98 transfusion of conditioned neutrophils in a neutropenic guinea pig model increased bacterial clearan

99 An established neutropenic guinea pig model of IPA caused by Aspergillu

100 llin/tazobactam alone in febrile, high-risk, neutropenic hematologic patients with cancer.

101 as crucial innate cellular effectors in the neutropenic host after active immunization.

102 lera toxin was found to be protective to the neutropenic host, and this phenotype can be replicated b

103 lethal bacterial infection in the profoundly neutropenic host.

104 the disease burden in immunocompromised and neutropenic hosts and causes serious congenital complica

105 ts, were found to accumulate in the lungs of neutropenic hosts challenged with killed or live-attenua

106 TRAIL-based therapy in neutropenic hosts may represent a novel antibacterial tr

107 The mechanism of this accumulation in neutropenic hosts was found to be augmented influx of DC

108 sis, a prototypic opportunistic infection in neutropenic hosts, is associated with marked accumulatio

109 negative patients, including pregnant women, neutropenic hosts, solid-organ or stem cell transplant r

110 DC traffic and phenotype and is specific to neutropenic hosts.

111 or the treatment of refractory infections in neutropenic hosts.

112 strategy for the prevention of infection in neutropenic hosts.

113 minated candidiasis as once-daily therapy in neutropenic hosts.

114 g following low dose spore inhalation in non-neutropenic hosts.

115 ctable in mouse lungs, serum and BALF during neutropenic IA, suggesting that GT may be useful to diag

116 n alveolus bilayer model and in the lungs of neutropenic immunocompromised mice.

117 However, not all neutropenic individuals develop infections, so the abili

118 The SIGNIFICANT (Simple Investigation in Neutropenic Individuals of the Frequency of Infection af

119 s and elevated expression of ELA2 in vivo in neutropenic individuals that GFI1 represses ELA2, linkin

120 cal management in well-appearing nonseverely neutropenic individuals.

121 rcellular adhesion molecule (ICAM)-1-/-, and neutropenic-induced mice were subjected to 70% hepatecto

122 Mice were made neutropenic; infected or not with Staphylococcus aureus,

123 ged grade 4 neutropenia (n = 4), and grade 5 neutropenic infection (n = 1).

124 < .001), hand-foot syndrome (P < .001), and neutropenic infection (P < .001).

125 h 25 mg lenalidomide developed a grade 4 non-neutropenic infection and died.

126 ns controversial for patients at low risk of neutropenic infection.

127 rse events were leukopenia (eight [32%]) and neutropenic infections (five [20%]).

128 of 1.9% (64 of 3,402) was mainly related to neutropenic infections (n = 56; 87.5%).

129 icant difference in toxicities was decreased neutropenic infections in patients treated with nelarabi

130 pecific defense mechanisms in the context of neutropenic infections is limited.

131 in source of early IFN-gamma in the lungs in neutropenic invasive aspergillosis, and this is an impor

132 Finally, in the context of neutropenic invasive aspergillosis, depletion of DCs res

133 In the particular setting of neutropenic leukemia patients with pulmonary infection,

134 Enrichment of GT in Aspergillus-infected neutropenic lung correlated with fungal burden and hypha

135 Interestingly, neutropenic lysozyme 2-diphtheria toxin A mice exhibited

136 Anti-PMN-treated mice became neutropenic (mean, 349 cells/microL), experiencing an 84

137 ony-stimulating factor increased survival of neutropenic mice after i.n. P. aeruginosa inoculation.

138 rmal mice but was outcompeted by MGAS2221 in neutropenic mice and had enhancements in expression of v

139 whereas the differences observed between the neutropenic mice and the saline-pretreated controls were

140 ion, myelin loss, and AQP4 loss in brains of neutropenic mice at 24 hours and 7 days, and increased s

141 e virulence defect was partially restored in neutropenic mice by adding gentamicin, an antibiotic tha

142 Wounds in neutropenic mice contained 100-fold fewer neutrophils th

143 Wound fluids from neutropenic mice contained 68% more TNF-alpha, 168% more

144 f granulocytes yielded 90% survivorship; all neutropenic mice died after the termination of treatment

145 48 mg/kg every 24 h in cohorts of normal and neutropenic mice for 5 days.

146 In neutropenic mice infected with wild-type A. fumigatus, i

147 alpha, suggesting the decreased survival in neutropenic mice is due to systemic shock.

148 Most importantly, neutropenic mice lacking neutrophil-derived TRAIL were p

149 An adoptive transfer of dendritic cells into neutropenic mice provided a protective effect during inv

150 Because identical ischemic injury in neutropenic mice resulted in milder renal insufficiency

151 At a high dose, neutropenic mice showed increased rates of survival comp

152 Non-neutropenic mice that were immunosuppressed with cortiso

153 n mutants in the lungs of wild-type (WT) and neutropenic mice using transposon sequencing (Tn-seq).

154 However, the bacterial load in the neutropenic mice was comparable to that of the saline-pr

155 Simulation of this dose in neutropenic mice was highly effective in methicillin-sen

156 res of lung injury in wild-type mice whereas neutropenic mice were protected from such injury.

157 We found that, in the lungs of neutropenic mice with invasive aspergillosis, NK cells w

158 rked induction of MCP-1/CCL2 in the lungs of neutropenic mice with invasive aspergillosis.

159 ciated with airway eosinophil recruitment in neutropenic mice with invasive pulmonary aspergillosis (

160 ATAK cells improved the survival of neutropenic mice with lethal disseminated candidiasis an

161 hen administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox signific

162 or only the first 24 h, or using genetically neutropenic mice), the cellular responses increased seve

163 In uninfected neutropenic mice, ATAK cells spread from the mesentery i

164 mAb-induced tumor reduction, abolished in neutropenic mice, could be restored in FcgammaR-deficien

165 mutational analysis, we demonstrate that, in neutropenic mice, elimination of the A. nidulans pH-resp

166 In neutropenic mice, intranasal (i.n.) doses of P. aerugino

167 In neutropenic mice, the LPS-induced NF-kB activation and T

168 accessory toxins in virulence is negated in neutropenic mice, which is consistent with a role of acc

169 in 51 genes still had significant defects in neutropenic mice, while mutants with insertions in 52 ge

170 sponse in the skin and was fully virulent in neutropenic mice.

171 utrophil-depleting antibodies or genetically neutropenic mice.

172 sing ace2Delta Candida glabrata infection in neutropenic mice.

173 abscesses and decreased disease severity in neutropenic mice.

174 that effectively treat lethal infections in neutropenic mice.

175 , like wild-type bacteria, it was lethal for neutropenic mice.

176 Ag-specific T cells and DCs was improved in neutropenic mice.

177 protective during invasive aspergillosis in neutropenic mice.

178 corticosteroids, but had normal virulence in neutropenic mice.

179 % for normal mice and 80%, 100%, and 70% for neutropenic mice.

180 , during pulmonary invasive aspergillosis in neutropenic mice.

181 rimental invasive pulmonary aspergillosis in neutropenic mice.

182 antifungal response against A. fumigatus in neutropenic mice.

183 s disease (CGD), hydrocortisone-treated, and neutropenic mice.

184 fit in the lungs of WT mice than in those of neutropenic mice.

185 protective during invasive aspergillosis in neutropenic mice.

186 s detected in 71% of sera and 50% of BALF of neutropenic mice; neither was detected in serum/BALF of

187 increased in adiponectin-deficient mice in a neutropenic model of invasive aspergillosis.

188 ltayaaA, and DeltaycgE mutants was higher in neutropenic mouse lungs, indicating that these genes enc

189 ced neutrophils (AINs) either in vitro or in neutropenic mouse model displayed strong bactericidal ac

190 enesis by A fumigatus both in vitro and in a neutropenic mouse model is mediated through secondary me

191 ted and reduced pulmonary fungal burden in a neutropenic mouse model of invasive aspergillosis.

192 In a neutropenic mouse model of IPA, treatment with posaconaz

193 Here, we show in a neutropenic mouse model that immunity induced by mucosal

194 coccus pneumoniae septicemia mouse model and neutropenic mouse thigh infection model using methicilli

195 al experiments (n = 6, including 5 using the neutropenic mouse thigh infection model), and clinical s

196 active against MRSA than free mupirocin in a neutropenic murine lung infection model.

197 aspergillosis, we used a well-characterized neutropenic murine model.

198 Subsequently, a neutropenic murine pneumonia model with simulated clinic

199 ted combinations were further validated in a neutropenic murine pneumonia model, using human-like dos

200 dynamically linked variable in the S. aureus neutropenic murine pneumonia model; the fAUC/MIC ratio r

201 In the Staphylococcus aureus neutropenic murine thigh-infection model, the ratio of t

202 constructed and found to be attenuated in a neutropenic, murine model of pulmonary infection.

203 Statistical analysis compared the neutropenic (n = 159) and nonneutropenic (n = 2421) pati

204 r WT thymocytes correct neutrophil counts in neutropenic nude mice.

205 Athymic nude mice are neutropenic or have near-normal neutrophil counts, depen

206 ad attenuated virulence, unless animals were neutropenic or lysozyme deficient.

207 idence of death related to port infection in neutropenic or nonneutropenic populations.

208 leukocytes; to produce disease in wild-type, neutropenic, or lysozyme-deficient rodents; and to induc

209 pment of fever and/or infections in afebrile neutropenic outpatients and recovery without complicatio

210 Secondary outcomes included: in afebrile neutropenic outpatients, infection-related mortality; in

211 mplications and overall mortality in febrile neutropenic outpatients.

212 ut when to begin empirical treatment after a neutropenic patient becomes febrile, whether and how to

213 gh-dose daptomycin (DAP) therapy failed in a neutropenic patient with bloodstream infection caused by

214 superiority trial, adult, febrile, high-risk neutropenic patients (FhrNPs) with hematologic malignanc

215 of A. fumigatus without developing disease, neutropenic patients and those receiving immunosuppressi

216 eages, and a partial response was defined in neutropenic patients as 100% increase in the absolute ne

217 ing of anti-gram-positive therapy to febrile neutropenic patients at risk of serious beta-lactam-resi

218 response to the invading fungi, not only in neutropenic patients but also in patients with normal or

219 Neutropenic patients continue to be at increased risk fo

220 Abdominal pain as a symptom in neutropenic patients continues to be a diagnostic and th

221 Data from 569 unique cases of VGS BSI in neutropenic patients from 2000 to 2010 at the MD Anderso

222 miting empiric anti-gram-positive therapy to neutropenic patients having at least 1 of these 3 risk f

223 is efficacious and safe in low-risk febrile neutropenic patients identified with the help of the MAS

224 Febrile neutropenic patients should receive initial doses of emp

225 associated with more diverse taxa within the neutropenic patients than the healthy subjects.

226 For example, the profound susceptibility of neutropenic patients to infection marks neutrophils (the

227 STR occurred only in neutropenic patients transfused with high bacterial load

228 al infections are accordingly encountered in neutropenic patients undergoing chemotherapy.

229 e compare two healthy individuals with seven neutropenic patients undergoing hematopoietic stem cell

230 Neutropenic patients were excluded.

231 Neutropenic patients were less likely to have a single p

232 and PCT levels were significantly higher in neutropenic patients with BSIs than in those without doc

233 idered the standard of treatment for febrile neutropenic patients with cancer, but this approach may

234 oral combination therapy in low-risk febrile neutropenic patients with cancer.

235 Neutropenic patients with fever and abdominal symptoms (

236 Furthermore, in neutropenic patients with lung injury, deterioration of

237 In neutropenic patients with severe sepsis or septic shock,

238 Granulocyte transfusions are beneficial in neutropenic patients with severe uncontrolled infection.

239 tions, especially among immunosuppressed and neutropenic patients, as well as a source of bacterial c

240 ntamination of platelets resulting in STR in neutropenic patients, failure of passive surveillance to

241 c infections in immunocompetent and severely neutropenic patients, respectively.

242 In neutropenic patients, we identified PRDM5 protein sequen

243 velopment of improved treatment regimens for neutropenic patients.

244 in the gastrointestinal tract, especially in neutropenic patients.

245 mbined remaining species to be isolated from neutropenic patients.

246 ause considerable morbidity and mortality in neutropenic patients.

247 s that causes life-threatening infections in neutropenic patients.

248 streptococcal endocarditis and infection in neutropenic patients.

249 e bacteria causing bloodstream infections in neutropenic patients.

250 ting that GT may be useful to diagnose IA in neutropenic patients.

251 n VGS causing bloodstream infection (BSI) in neutropenic patients.

252 of AFI, which was successfully treated in a neutropenic pediatric patient.

253 ssary antibiotic use in febrile, nonseverely neutropenic pediatric patients with cancer.

254 Prophylaxis was administered during the neutropenic period following each chemotherapy cycle.

255 the risk of infection is greatest during the neutropenic period immediately following transplant, pat

256 G-CSF shortened the posttransplantation neutropenic period, but did not affect days +30 and +100

257 g placebo for seven days during the expected neutropenic period.

258 f the cathelicidin gene, Cnlp, were rendered neutropenic prior to cutaneous infection.

259 cultures in experiments using BAL fluid from neutropenic rabbits with experimentally induced IPA defi

260 sive pulmonary aspergillosis in persistently neutropenic rabbits.

261 sive pulmonary aspergillosis in persistently neutropenic rabbits.

262 and protect against microbial invasion in a neutropenic rat model of gram-negative sepsis.

263 In the neutropenic rat model, daily administration of WAY-20219

264 tested in the murine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and th

265 When the proteins were injected into neutropenic rats, the group injected with PEG-GCSF showe

266 was not as efficient as PEG-GCSF in treating neutropenic rats.

267 g capability (decreased bacterial burden) in neutropenic recipient mice in both peritonitis and bacte

268 e effects for TH and TCH, respectively, were neutropenic-related complications, 29% and 23%; thromboc

269 XT was associated with higher GI, skin, and neutropenic-related toxicities.

270 Dose limiting toxicity comprising neutropenic sepsis (one patient) and grade 3 fatigue (on

271 n the phase 2 combination cohort (one due to neutropenic sepsis and one due to Escherichia coli sepsi

272 n the treatment of physician's choice group (neutropenic sepsis and septic shock).

273 y dosing scheme; 2 of these patients died of neutropenic sepsis complications.

274 itabine plus cisplatin, but after two cycles neutropenic sepsis developed, which required a prolonged

275 tment-related deaths occurred; one caused by neutropenic sepsis in a patient with concurrent cytokine

276 One elderly patient died of neutropenic sepsis in the first brentuximab-AVD cycle.

277 One fatal event of neutropenic sepsis was reported in a patient allocated r

278 n the COMBO study, the MTD was 22 microg/kg (neutropenic sepsis).

279 b emtansine group [metabolic encephalopathy, neutropenic sepsis, and acute myeloid leukaemia]).

280 amethasone group (one each of unknown cause, neutropenic sepsis, myocarditis, and Stevens-Johnson syn

281 One fatal toxic effect, neutropenic sepsis, occurred in the primary-chemotherapy

282 One death, related to neutropenic sepsis, occurred on study.

283 were three treatment-related deaths owing to neutropenic sepsis.

284 There was no neutropenic fever or neutropenic sepsis.

285 CX group died of suspected treatment-related neutropenic sepsis.

286 ) robustly lowered the bacterial burden in a neutropenic Staphylococci murine infection model.

287 mpound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model.

288 The initial neutropenic state fostered an environment of increased d

289 nts was inhibited, without rendering animals neutropenic, suggesting an effect of G-CSF receptor bloc

290 of inflammatory cytokines, and when rendered neutropenic the mortality difference was abrogated.

291 ioavailability and shows efficacy in a mouse neutropenic thigh infection model.

292 o PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains wi

293 In vivo mouse systemic infection and neutropenic thigh model experimental results confirmed t

294 th infectious risk, it permits assessment of neutropenic timepoints that were previously inaccessible

295 re quite common, whereas emergencies such as neutropenic typhlitis, pancreatitis, and acute haemolysi

296 GT levels were higher in neutropenic versus CGD or steroid-treated lungs.

297 Further work was undertaken in neutropenic versus non-neutropenic animals.

298 chest port removal in adults when placed in neutropenic versus nonneutropenic patient groups.

299 MAGP2-deficient mice are neutropenic, which contrasts with monocytopenia describe

300 staining was greater in cells isolated from neutropenic wounds than in those from control wounds.